|Day's Range||9.70 - 9.70|
Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.63% and 19.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, ...
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2019 financial results ...
The FDA-approved labeling has now been updated to indicate that Orenitram delays disease progression when used in conjunction with an approved oral background PAH therapy. The primary efficacy endpoint of the FREEDOM-EV study was time to first clinical worsening (morbidity or mortality) event.
If you're interested in United Therapeutics Corporation (NASDAQ:UTHR), then you might want to consider its beta (a...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Thanks to the Dodd-Frank Act passed back in 2008, we now have some new information in the annual reports public companies are required to file: how the CEO's compensation compares to that of rank-and-file employees. Some public companies are outright exempt for the reporting rule, including: companies with revenue of less than $1 billion up to five years after an initial public offering, smaller reporting companies (defined as having less than $75 million worth of stock stock that isn't held by management or major investors) and foreign private issuers.
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to...
VANCOUVER , Sept. 12, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S. Food and Drug Administration (FDA) has accepted for review United Therapeutics Corporation's (UTHR) New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020 . Trevyent is a drug-device combination product that combines two-day, single use, disposable PatchPump® technology with treprostinil, for the subcutaneous treatment of PAH. Correvio holds commercial rights to Trevyent for the international markets of Europe and the Middle East and expects to file regulatory submissions for Trevyent in Europe in mid-2020.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020.
MannKind Corp (MNKD) reported financial results for their second quarter ending June 30th and provided a business update. Both gross and net product sales set new records, as did product margin. As a reminder, Afrezza is sold in 4-,8- and 12-unit cartridges.
NEW YORK, Aug. 19, 2019 -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a.
Martine Rothblatt became the CEO of United Therapeutics Corporation (NASDAQ:UTHR) in 2016. First, this article will...